- Cybin has completed more than 20 pre-clinical studies in record time.
- Company is advancing two new therapeutic candidates with enhanced, improved properties.
- Drug candidates are designed to treat serious psychiatric conditions with high unmet medical needs.
Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, has completed key research studies both in vitro and in vivo. The company recently announced that it had completed its 20th pre-clinical study and had progressed two psychedelic investigational new drug candidates: CYB003 and CYB004 (https://ibn.fm/jDvFz).
The studies were completed in record time, the company reported, in part because of close collaboration with its partners and contractors. “Excellent teamwork and fully supportive partners have greatly facilitated the advancement of these two new therapeutic candidates with enhanced and improved properties,” said Cybin chief R&D officer Michael Palfreyman. “We look forward to rapid progress towards clinical studies.”
The completed studies were focused on evaluating proprietary Cybin technologies, and more than 20 definitive research studies designed by the Cybin scientists were conducted. Results of the studies have led to the progression CYB003 and CYB004, two proprietary psychedelic therapeutics which have entered into full IND-enabling studies.
These studies are in preparation for upcoming clinical testing designed to analyze the effectiveness of these therapeutics in the treatment of serious psychiatric conditions with high unmet medical needs. The company has also initiated an API manufacturing contract with a strategic pharmaceutical manufacturing partner. According to Cybin, the pre-clinical studies of CYB003 and CYB004 candidates included API synthesis and optimization to prove that the two psychedelic molecules show significant in vivo modifications of pharmacokinetics consistent with proof of concept.
These two studies are only a part of Cybin’s impressive pipeline. Currently the company is developing more than 50 proprietary psychedelic molecules and multiple proprietary delivery mechanisms and supportive technology platforms. The company plans to continue to progress its novel next-generation psychedelics based on well-known scaffolds including psilocybin, DMT, MDMA with improved bioavailability and optimized pharmacokinetic profiles to provide shorter duration of action with the potential for reduced side effects.
“Our internal research and development team, along with an extensive network of partners, has progressed CYB003 and CYB004 into IND-enabling studies at an impressive pace,” said Cybin CEO Doug Drysdale. “I am in no doubt we have the best team in this sector and the right team to progress these exciting future treatments into clinical studies over the next 12 months.”
Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug- discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.